|
THE SENATE |
S.B. NO. |
446 |
|
THIRTY-SECOND LEGISLATURE, 2023 |
S.D. 1 |
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO PRESCRIPTION DIGITAL THERAPEUTICS.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
(1) Any potential short-term and long-term financial effects on the State for the pilot program, which shall include:
(A) The demographics and needs of persons with substance use disorder or opioid use disorder within the State;
(B) The costs and benefits of integrating different approved prescription digital therapeutic products into treatment programs in the State, including any security and privacy considerations; and
(C) How various governmental entities can best help provide medical assistance coverage of the approved prescription digital therapeutic products for the treatment of substance use disorders and opioid use disorders, including any immediate and ongoing availability of federal funds;
(2) Any oversight and regulatory requirements necessary to implement the pilot program, including any potential hurdles and strategies to address the potential hurdles;
(3) Any effect of the pilot program on relevant existing health care providers and health care organizations, programs, and agencies;
(4) Any other beneficial alternative options;
(5) Which agency or agencies are best equipped to administer the pilot program, including how the pilot program should be structured;
(6) Which facility or facilities in the State are best suited to implement the pilot program;
(7) Which approved prescription digital therapeutic products best fit the needs of persons with substance use disorder or opioid use disorder in the State;
(8) How to evaluate the outcomes of the pilot program, including preferred frameworks to gauge the impact of the approved prescription digital therapeutic products, especially when used in conjunction with other treatments and therapies; and
(9) Other considerations necessary to help health care decision-makers accurately anticipate the impact of approved prescription digital therapeutic products on the overall delivery of health care in the State.
(b)
The department of health shall submit a report of its findings and
recommendations from the study, including any proposed legislation, to the legislature
no later than twenty days prior to the convening of the regular session of 2024.
Report Title:
Department of Health; Feasibility Study; Pilot Program; Prescription Digital Therapeutics; Outpatient Treatment; Substance Use Disorder; Opioid Use Disorder
Description:
Requires the Department of Health to conduct a study to determine the feasibility of implementing a pilot program to integrate prescription digital therapeutic products approved by the federal Food and Drug Administration in outpatient treatment programs for persons with substance use disorder and persons with opioid use disorder in the State. Requires a report to the Legislature. Effective 12/31/2050. (SD1)
The summary description
of legislation appearing on this page is for informational purposes only and is
not legislation or evidence of legislative intent.